Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use ...

I am deeply troubled by the growing distrust of science in our society, just at the time when its insights are most needed.

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on BioNTech SE (BNTX – Research Report), ...

The revamped vaccine is an effort by regulators and vaccine makers to keep pace with the virus, which continues to evolve ...

The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...

NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with ...

The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...